Nivolumab in salivary gland cancers: confronting the challenges of unlocking the therapeutic benefits of immunotherapy for rare diseases.
作者信息
Desilets Antoine, Ho Alan L
机构信息
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Department of Medicine, Weil Medical College of Cornell University, New York, New York, USA.
出版信息
BMJ Oncol. 2023 Oct 30;2(1):e000214. doi: 10.1136/bmjonc-2023-000214. eCollection 2023.
Abstract
摘要
相似文献
1
Nivolumab in salivary gland cancers: confronting the challenges of unlocking the therapeutic benefits of immunotherapy for rare diseases.纳武利尤单抗治疗唾液腺癌：应对为罕见病解锁免疫治疗益处的挑战
BMJ Oncol. 2023 Oct 30;2(1):e000214. doi: 10.1136/bmjonc-2023-000214. eCollection 2023.
2
NISCAHN: a phase II trial of nivolumab in patients with salivary gland carcinoma (Unicancer ORL-08).NISCAHN：纳武单抗治疗唾液腺癌患者的II期试验（Unicancer ORL-08）。
BMJ Oncol. 2023 Oct 30;2(1):e000065. doi: 10.1136/bmjonc-2023-000065. eCollection 2023.
3
Complete Response to Nivolumab of Resected Adenocarcinoma NOS With Parotid Gland Origin and Lung Metastasis.肺转移性腺癌NOS 伴腮腺起源的完全缓解对nivolumab 的反应。
In Vivo. 2022 Nov-Dec;36(6):2840-2843. doi: 10.21873/invivo.13023.
4
Nivolumab in patients with rare head and neck carcinomas: A single center's experience.纳武利尤单抗治疗罕见头颈癌患者：单中心经验
Oral Oncol. 2020 Feb;101:104359. doi: 10.1016/j.oraloncology.2019.07.002. Epub 2019 Jul 9.
5
Nivolumab as a Promising Treatment Option for Metastatic Salivary Duct Carcinoma.尼伏鲁单抗作为转移性涎腺癌有前途的治疗选择。
J Immunother. 2024 Sep 1;47(7):258-262. doi: 10.1097/CJI.0000000000000513. Epub 2024 Mar 28.
6
Unlocking the Future: Bioprinting Salivary Glands-From Possibility to Reality.开启未来：生物打印唾液腺——从可能性到现实
J Funct Biomater. 2024 Jun 1;15(6):151. doi: 10.3390/jfb15060151.
7
Salivary Gland Cancers.唾液腺癌
Hematol Oncol Clin North Am. 2021 Oct;35(5):973-990. doi: 10.1016/j.hoc.2021.05.011.
8
Nivolumab for recurrent or metastatic head and neck cancer patients with non-squamous cell carcinoma and/or a primary subsite excluded from CheckMate141, a retrospective study.纳武利尤单抗治疗 CheckMate141 回顾性研究中排除的非鳞状细胞癌和/或原发部位以外的复发性或转移性头颈部癌症患者。
Oral Oncol. 2022 Jul;130:105932. doi: 10.1016/j.oraloncology.2022.105932. Epub 2022 May 27.
9
A molecular guide to systemic therapy in salivary gland carcinoma.唾液腺癌全身治疗的分子指南。
Head Neck. 2023 May;45(5):1315-1326. doi: 10.1002/hed.27307. Epub 2023 Mar 1.
10
Multicentre, retrospective study of the efficacy and safety of nivolumab for recurrent and metastatic salivary gland carcinoma.多中心、回顾性研究纳武利尤单抗治疗复发性和转移性涎腺癌的疗效和安全性。
Sci Rep. 2020 Oct 12;10(1):16988. doi: 10.1038/s41598-020-73965-6.
本文引用的文献
1
Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial.纳武利尤单抗联合伊匹单抗治疗晚期涎腺癌：一项 2 期试验。
Nat Med. 2023 Dec;29(12):3077-3089. doi: 10.1038/s41591-023-02518-x. Epub 2023 Aug 24.
2
Phase II Clinical Trial of Axitinib and Avelumab in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma.阿昔替尼和avelumab 治疗复发性/转移性腺样囊性癌患者的 II 期临床试验。
J Clin Oncol. 2023 May 20;41(15):2843-2851. doi: 10.1200/JCO.22.02221. Epub 2023 Mar 10.
3
Evaluation of pembrolizumab monotherapy in patients with previously treated advanced salivary gland carcinoma in the phase 2 KEYNOTE-158 study.评估 KEYNOTE-158 研究中先前治疗的晚期唾液腺癌患者中单独使用派姆单抗的疗效。
Eur J Cancer. 2022 Aug;171:259-268. doi: 10.1016/j.ejca.2022.05.007. Epub 2022 Jun 28.
4
Randomized Phase II Study of Axitinib versus Observation in Patients with Recurred or Metastatic Adenoid Cystic Carcinoma.阿昔替尼对比观察用于复发性或转移性腺样囊性癌患者的随机II期研究
Clin Cancer Res. 2021 Oct 1;27(19):5272-5279. doi: 10.1158/1078-0432.CCR-21-1061.
5
A Randomized Phase 2 Study of Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma.帕博利珠单抗联合或不联合放疗用于复发性或转移性腺样囊性癌患者的随机2期研究。
Int J Radiat Oncol Biol Phys. 2021 Jan 1;109(1):134-144. doi: 10.1016/j.ijrobp.2020.08.018. Epub 2020 Aug 8.
6
The Immune Microenvironment and Neoantigen Landscape of Aggressive Salivary Gland Carcinomas Differ by Subtype.侵袭性唾液腺癌的免疫微环境和新抗原景观按亚型不同而有所差异。
Clin Cancer Res. 2020 Jun 15;26(12):2859-2870. doi: 10.1158/1078-0432.CCR-19-3758. Epub 2020 Feb 14.
7
A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer.帕博利珠单抗和伏立诺他治疗复发性转移性头颈部鳞状细胞癌和唾液腺癌的 II 期临床试验。
Clin Cancer Res. 2020 Feb 15;26(4):837-845. doi: 10.1158/1078-0432.CCR-19-2214. Epub 2019 Dec 3.
8
Phase II Study of Lenvatinib in Patients With Progressive, Recurrent or Metastatic Adenoid Cystic Carcinoma.仑伐替尼治疗进展性、复发性或转移性腺样囊性癌患者的 II 期研究。
J Clin Oncol. 2019 Jun 20;37(18):1529-1537. doi: 10.1200/JCO.18.01859. Epub 2019 Apr 2.
9
Defining the Most Appropriate Primary End Point in Phase 2 Trials of Immune Checkpoint Inhibitors for Advanced Solid Cancers: A Systematic Review and Meta-analysis.定义晚期实体瘤免疫检查点抑制剂的 2 期临床试验最合适的主要终点：系统评价和荟萃分析。
JAMA Oncol. 2018 Apr 1;4(4):522-528. doi: 10.1001/jamaoncol.2017.5236.
Zotero 插件